A Phase 2/3 interventional study of Azithromycin in Pediatric Asthma and Critical Illness, sponsored by Johns Hopkins All Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Johns Hopkins All Children's Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Azithromycin (AZI), a macrolide antibiotic, has been applied for adult and pediatric respiratory pathology to alter immune system response.1 For pediatric critical asthma (CA), a term used to describe a critically ill child hospitalized with an asthma exacerbation requiring an intensive care unit (PICU) hospitalization, the investigator's prior research has revealed 1 in 10 will receive AZI.2 Yet, the application of AZI in this setting is poorly studied nor is clear if, and to what degree AZI alters the immune response in conjunction with systemic corticosteroids traditionally applied in CA.
In this proposal, the investigators aim to characterize a respiratory epithelial inflammatory biomarker, periostin, among children with CA with and without exposure to AZI. The investigators hypothesize children receiving AZI will have lower periostin levels. As a secondary analysis, the investigators will describe the rates of adverse events related to AZI (previously not done) and explore differences in clinical and physiologic CA efficacy markers.
1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.
This study's planned enrollment of 100 is above the median of 90 across 930 interventional studies indexed under Critical Illness.
Browse Critical Illness studies →Johns Hopkins All Children's Hospital is the lead sponsor of 25 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive Azithromycin 10mg/kg/dose (max dose 500mg) once daily for 3 days.
Drug: Azithromycin
Participants will receive standard care without Azithromycin.
10mg/kg/dose (max dose 500mg) once daily for 3 days
Also known as: Zithromax
Plasma Periostin Levels and Degree of Change (e.g., Slope) - Primary Physiologic Efficacy Endpoint
ng/dL
Time frame: 24 hours, 48 hours, and 72-hours following enrollment
Drug-related adverse event rate (Primary Safety Endpoint)
cumulative incidence rate
Time frame: During hospitalization, approximately 3 days
Length of Stay (Secondary Clinical Efficacy Endpoint)
Measured in Days, from Hospitalization in ICU through Discharge from ICU
Time frame: During hospitalization, approximately 3 days
Duration of continuous albuterol (Secondary Clinical Efficacy Endpoint)
Measured in Hours from ICU hospitalization through discharge
Time frame: During hospitalization, approximately 3 days
Composite use of adjunct asthma treatments (Secondary Clinical Efficacy Endpoint)
Cumulative Frequency of Exposure, from ICU Hospitalization through ICU discharge
Time frame: During hospitalization, approximately 3 days
Transcutaneous carbon dioxide levels (Secondary physiologic efficacy Endpoint)
Measured in mmHg of Carbon Dioxide, peak values measured daily at each study visit
Time frame: Enrollment, Day 1, Day 2, Day 3, at ICU Discharge
Plan to share: No — No plan to share with other researchers.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azithromycin
Johns Hopkins All Children's Hospital